Navigation Links
Nano-particles effective in killing cancer with one-two punch of chemotherapeutics

Research studies, based at the University of Pennsylvania, demonstrate that biodegradable nano-particles containing two potent cancer-fighting drugs are effective in killing human breast tumors. The unique properties of the hollow shell nano-particles, known as polymersomes, allow them to deliver two distinct drugs, paclitaxel, the leading cancer drug known by brand names such as Taxol, and doxorubicin directly to tumors implanted in mice. Their findings, presented online in the journal Molecular Pharamaceutics, illustrate the broad clinical potential of polymersomes.

"The system provides a number of advantages over other Trojan horse-style drug delivery system, and should prove a useful tool in fighting a number of diseases," said Dennis Discher, a professor in Penn's School of Engineering and Applied Science and a member of Penn's newly established Institute for Translational Medicine and Therapeutics. "Here we show that drug-delivering polymersomes will break down in the acidic environment of the cancer cells, allowing us to target these drugs within tumor cells."

One key feature of molecular mechanism involves putting pores in the cancer cell's membranes and has been simulated with supercomputers by Michael F. Klein and Goundla Srinivas of Penn's Department of Chemistry. While cell membranes and liposomes (vesicles often used for drug-delivery) are created from a double layer of fatty molecules called phospholipids, a polymersome is comprised of two layers of synthetic polymers. The individual polymers are degradable and considerably larger than individual phospholipids but have many of the same chemical features. This results in a structure that looks like a very small cell or virus.

Discher and his colleagues take advantage of the polymersome properties to ferry their drug combination to the tumor. The large polymers making up the shell allow paclitaxel, which is water-insoluble, to embed within the shell. Doxorubicin, which
'"/>

Source:University of Pennsylvania


Page: 1 2

Related biology news :

1. Combination therapy boosts effectiveness of telomere-directed cancer cell death
2. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
3. Boosting HIV screening can increase survival and is cost effective
4. Live vaccines more effective against horse herpes virus
5. Man-made wetlands effectiveness similar to natural marsh
6. Wake Forest scientists find new combination vaccine effective against plague
7. UCLA study assesses cost-effectiveness of Hepatitis B drugs
8. New study: Sexually transmitted disease treatment can be effectively administered by sex partners
9. New vaccine protects more effectively against tuberculosis
10. Harmless virus may hold key to more effective HIV drug discovery
11. Structures of marine toxins provide insight into their effectiveness as cancer drugs
Post Your Comments:
(Date:5/18/2015)... -- Fingerprint Cards (FPC) has received an order ... FPC1035 from one if its module partners. Deliveries are planned ... and the sensors will be used by smartphone manufacturers in ... hereby amount to 740 MSEK to date. In addition to ... a number of smaller orders not separately communicated amounting to ...
(Date:5/11/2015)... , May 11, 2015  Through a well-rounded UAS delegation ... had a strong showing at AUVSI,s Unmanned 2015 conference ... of Ohio,s UAS industry met with ... from all points along the UAS ecosystem. ... (DDC) Vice President for Aerospace Rich Knoll . "If ...
(Date:5/7/2015)... GOTHENBURG, Sweden , May 7, 2015 /PRNewswire/ ... new touch fingerprint sensors, FPC1022 and FPC1035, FPC,s ... FPC1022 and FPC1035 are mainly considered for integration ... decreased size gives smartphone OEMs increased possibilities to ... portfolio. The decreased size also improves possibilities for ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... , MOUNTAIN VIEW, CA January 11, 2011 23andMe ... to be the 10 most interesting and significant genetic findings ... the role of genetics in personal health and human development. ... at a phenomenal rate," stated Anne Wojcicki, co-founder and CEO ...
... bit of a Jekyll and Hyde relationship with mercury, ... National Laboratory have made a discovery that ultimately could ... known that microbes in aquatic environments make methylmercury, a ... they also know that nature and other types of ...
... it cracks or otherwise fails, it proves brittle, shattering ... be toughthey resist shatteringbut are also relatively weak; they ... says Marios Demetriou, a senior research fellow at the ... being both strong and tougha combination called damage tolerance, ...
Cached Biology News:23andMe presents top 10 most interesting genetic findings of 2010 223andMe presents top 10 most interesting genetic findings of 2010 323andMe presents top 10 most interesting genetic findings of 2010 423andMe presents top 10 most interesting genetic findings of 2010 523andMe presents top 10 most interesting genetic findings of 2010 623andMe presents top 10 most interesting genetic findings of 2010 723andMe presents top 10 most interesting genetic findings of 2010 823andMe presents top 10 most interesting genetic findings of 2010 923andMe presents top 10 most interesting genetic findings of 2010 1023andMe presents top 10 most interesting genetic findings of 2010 1123andMe presents top 10 most interesting genetic findings of 2010 1223andMe presents top 10 most interesting genetic findings of 2010 1323andMe presents top 10 most interesting genetic findings of 2010 1423andMe presents top 10 most interesting genetic findings of 2010 1523andMe presents top 10 most interesting genetic findings of 2010 1623andMe presents top 10 most interesting genetic findings of 2010 1723andMe presents top 10 most interesting genetic findings of 2010 18Natural dissolved organic matter plays dual role in cycling of mercury 2Caltech-led team creates damage-tolerant metallic glass 2Caltech-led team creates damage-tolerant metallic glass 3Caltech-led team creates damage-tolerant metallic glass 4
(Date:5/21/2015)...  The EveryLife Foundation for Rare Diseases applauded ... Amy Klobuchar (D-MN) today for introducing the ... or OPEN ACT. Supported by more ... bipartisan legislation promises to rapidly bring hundreds of ... patients by incentivizing drug makers to "repurpose" approved ...
(Date:5/21/2015)... 21, 2015 W. R. Grace ... facility in Worms, Germany has received good manufacturing ... of the International Pharmaceutical Excipient Council (IPEC) Foundation. ... produce its SYLOID® FP brand of pharmaceutical grade ... following the Curtis Bay, Maryland (USA) and Sorocaba, ...
(Date:5/21/2015)... ANGELES , May 21, 2015  CytRx ... and development company specializing in oncology, today announced ... clinical trial with aldoxorubicin for the treatment of ... brain cancer.  The open-label, multisite trial is designed ... aldoxorubicin in patients whose tumors have progressed following ...
(Date:5/21/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ) ... Global Survey on Flow Cytometry Adoption Trends" ... goal of this research is to analyze the ... information the survey seeks to collect include factors ... used applications for flow cytometers, respondents, most preferred ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
... (PBS-Bio) decodes the workings of drugs made by two private firms ... the American Association for Cancer Research. The conference runs April ... The presentations will be given on April 5. In ... a Belgian firm, affects two genes MCL1 and MYC. ...
... Ill. With the first observation of thermoelectric effects ... graphene transistors have a nanoscale cooling effect that reduces ... professor William King and electrical and computer engineering professor ... the April 3 advance online edition of the journal ...
... cannot be focused to spot sizes smaller than half ... approach to beat this diffraction limit is based on ... radiofrequency counterparts. They have the ability to concentrate (focus) ... orders of magnitude smaller than what conventional lenses can ...
Cached Biology Technology:TGen and PBS-Bio presents 2 abstracts at AACR conference 2Self-cooling observed in graphene electronics 2Transmission lines for nanofocusing of infrared light 2Transmission lines for nanofocusing of infrared light 3